EM703 improves bleomycin-induced pulmonary fibrosis in mice by the inhibition of TGF-β signaling in lung fibroblasts
2006

EM703 Improves Lung Fibrosis in Mice

Sample size: 8 publication Evidence: high

Author Information

Author(s): Li Ying Ji, Azuma Arata, Usuki Jiro, Abe Shinji, Matsuda Kuniko, Sunazuka Toshiaki, Shimizu Takako, Hirata Yukiyo, Inagaki Hirofumi, Kawada Tomoyuki, Takahashi Satoru, Kudoh Shoji, Omura Satoshi

Primary Institution: Nippon Medical School, Tokyo, JAPAN

Hypothesis

Does EM703 have anti-inflammatory and antifibrotic effects in a model of bleomycin-induced lung injury?

Conclusion

EM703 improves bleomycin-induced pulmonary fibrosis in mice by inhibiting TGF-β signaling in lung fibroblasts.

Supporting Evidence

  • EM703 significantly reduced the number of macrophages and neutrophils in bronchoalveolar lavage fluid.
  • Histopathological assessment showed that EM703 inhibited bleomycin-induced pulmonary fibrosis.
  • EM703 treatment led to a significant reduction in hydroxyproline content in lung tissues.

Takeaway

Researchers found that a new drug called EM703 helps mice with lung damage heal better by reducing inflammation and stopping scar tissue from forming.

Methodology

The study used male ICR mice, administering bleomycin and EM703, and assessed lung tissue and cell populations in bronchoalveolar lavage fluid.

Participant Demographics

Seven-week-old male ICR mice

Statistical Information

P-Value

p<0.01

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/1465-9921-7-16

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication